Pfizer prepares LITFULO filings. Pfizer stock sits 2.72 percent below its high.
Published on 10/06/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Pfizer Inc. (ISIN US7170811035) is preparing worldwide LITFULO applications after positive vitiligo study results dated October 4, 2026, while Pfizer stock sat 2.72 percent below its EUR 25.33 52-week high. Boerse Express reported that Phase 3 TRANQUILLO studies showed improved facial and total-body repigmentation versus placebo after 52 treatment weeks.
LITFULO advances toward regulators
The company plans submissions to the US Food and Drug Administration and the European Medicines Agency, according to Boerse Express on October 4, 2026. The same report said Tilrekimig reached its Phase 2 target in atopic dermatitis, adding a second late-stage immunology development to the pipeline.
The clinical update matters because Pfizer is balancing pipeline investment against weaker COVID product demand. The company is using late-stage assets such as LITFULO and Tilrekimig to build future growth beyond the pandemic portfolio.
Revenue guidance moves higher
In its second-quarter 2026 earnings call on August 4, Pfizer reported USD 15.00 billion in revenue, up 1 percent operationally year over year, while adjusted diluted earnings per share reached USD 0.77. Yahoo Finance records that adjusted diluted earnings per share exceeded expectations, while reported loss per share was USD 0.04.
Management raised the midpoint of full-year 2026 revenue guidance by USD 0.50 billion, from a prior range of USD 59.5 billion-USD 60.5 billion to USD 60.5 billion-USD 62.5 billion, according to Yahoo Finance. The guidance change provides a quantified counterweight to the near-term pressure from declining COVID revenue.
Stock remains below its yearly high
Pfizer's primary listing is on the NYSE, and its market capitalization was USD 156.1 billion as of October 6, 2026. Its Tradegate range for the 52 weeks was EUR 20.75 to EUR 25.33 on October 6, 2026, placing the EUR 24.64 quote 2.72 percent below the high.
Pfizer was last at EUR 24.64 on Tradegate on October 6, 2026 at 10:29 a.m. CEST, versus the Tradegate close of EUR 24.44 on October 5, 2026. Price source: substitute price Tradegate, Lang & Schwarz without data set.
Pfizer stock facts
- Company: Pfizer Inc.
- ISIN: US7170811035
- WKN: 852009
- Ticker: PFE
- Primary exchange: NYSE
- Substitute price Tradegate (as of October 6, 2026, 10:29 a.m. CEST): EUR 24.64
- Change versus prior close: plus 0.82 percent
- Prior close Tradegate (October 5, 2026): EUR 24.44
- Market capitalization: USD 156.1 billion (as of October 6, 2026)
- 52-week range: EUR 20.75-EUR 25.33 (as of October 6, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
